International Journal of MS Care (IJMSC)’s Post

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/erNMsDVi

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/eWGeWyPY

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/epbYkP28

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/gSMcnfF6

#ischemicstroke #Bcell #phenotype #phagocyticcapability #chemotacticfunction A novel phenotype of B cells associated with enhanced phagocytic capability and chemotactic function after ischemic stroke https://lnkd.in/gCga3r2p Accumulating evidence has demonstrated the involvement of B cells in neuroinflammation and neuroregeneration.  However, the role of B cells in ischemic stroke remains unclear.  In this study, we identified a novel phenotype of macrophage-like B cells in brain-infiltrating immune cells expressing a high level of CD45.  Our results provide a new perspective on the phagocytic capability and chemotactic function of B cells in the ischemic brain.  These cells may serve as an immunotherapeutic target for regulating the immune response of ischemic stroke.

💡Research Seminar || 5th July 2024, 12PM || MD9 Level 1 Workshop Room Registration Link: https://lnkd.in/gjzjUdYB Title: Protein misfolding in ALS: From disease mechanism to therapeutic strategy The research of Joseph Huang’s group is directed toward unraveling the signaling events that direct protein trafficking in co-translational protein folding and toward understanding the role that protein misfolding plays in neuron degenerative diseases. At the moment, this group is focusing on the TAR (trans-activation response element) DNA binding protein (TDP-43) in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Dementia (FTLD). Studies are in progress to elucidate the participation of the chaperones in preventing protein aggregation and develop new therapeutic strategies as well as diagnostic tools against ALS and Huntington’s disease. As a member of the Neuroscience Program in Academia Sinica, Dr. Huang’s team is also investigating the proteinopathy of misfolded proteins in neurodegenerative diseases in general.

The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) will be hosting a webinar on May 2, 2024 from 1-2 pm ET, to introduce their new two-stage application and review process for OTA-24-013, NeuroNEXT Clinical Trials Stage 1 Preliminary Application, and OTA-24-014, NeuroNEXT Clinical Trials Stage 2 Protocol Application. #NeuroNEXT provides robust, standardized, and accessible infrastructure, designed to facilitate development and conduct of #Phase2 #clinicaltrials or #biomarkerstudies focused on #neurologicaldisease in pediatric and adult populations. More about the event can be found here: https://lnkd.in/eHH7gRnH

Excited to see how this collaboration yields new biomarkers with the following three distinct but interrelated goals: ✅ Monitor ALS disease progression and treatment efficacy across cohorts from multiple participating institutions ✅ Innovate therapeutic strategies and diagnostic tools by better understanding the metabolic landscape of motor neuron cells in ALS patients ✅ Drive precision medicine advances by subsetting patients based on their unique metabo-phenotype.

❣ Special Issue Sharing 📑 Title: Glia and Neuroprotection 👨⚕️ Guest Editor: Prof. Jose Miguel S. 👉 "Neuroprotective astroglial response to neural damage and its relevance to affective disorders" 📎 DOI: https://lnkd.in/gepyfCU5 👉 "Innate and adaptive glial cell responses in Alzheimer’s disease" 📎 DOI: https://lnkd.in/ekQfPqpZ 👉 "Blockage of thrombospondin 4 secreted by spinal astrocytes may be a promising therapeutic target in the treatment of neuropathic pain" 📎 DOI: https://lnkd.in/eGF4iNEj 📌 Potential topics include, but are not limited to: · Glial cell response and neuroprotection · Neuroinflammation and glial cell responses · Innate and adaptive glia responses in the CNS · Brain neuroprotection · Cross-talk between the glial cells and neurons · Brain damage and neuroprotective therapy · Effects of aging on the function of glial cells · Preclinical studies of neuroprotective therapeutics #glial cells; #neuroprotection; #central nervous system; #neuronal survival, #astrocytes

New therapies on the horizon: Targeted protein degradation in neuroscience With the first PROTAC protein degrader ARV-102 entering phase I clinical trials earlier this year to treat Parkinson's disease and progressive supranuclear palsy targeting the kinase LRRK2, it's a perfect time to welcome a mini review exploring the burgeoning advancements in TPD technologies, and it's promising applications in neuroscience research while highlighting at the same time the complexity of bringing CNS-targeted PROTACs to clinical development. https://lnkd.in/gDMgumyW